Ovensa Inc. is a Canadian biotechnology company that takes advantage of its proprietary delivery technology platforms to solve pharmacokinetic challenges or to reformulate off-patent drugs without modifying or denaturing them.
Ovensa's partners could benefit from its technology platforms for developing drugs or other bioactives with delayed delivery, in situ targeting, improved bioavailability and offering better patient compliance. We work with the pharmaceutical, biomedical, cosmetic and health supplement industries.
Montreal, January 12, 2015 – Aligo is proud to announce the granting of a worldwide exclusive license for all applications to Ovensa Inc. for the production and commercialization of trimethyl chitosan (TMC), a derivative of chitosan, a technology emanating from the University du Québec à Rimouski (UQAR). View full press release...